RxDoctor Payments Data

Ajit Singh, MD

Internal Medicine · Coconut Creek, FLNPI 1427008838

Payments from drug & device makers

$2,380in general payments, 2019–2025

Across 92 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$704
  • Novartis$220
  • Abbott$206
  • Astellas Pharma US Inc$170
  • Bayer$162
  • Novo Nordisk$143
  • plus $774 from 16 others

What the payments were for

  • Food & beverage$2,28196%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,380 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$108,193
Medicare patients
356
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$47,260
JardianceEmpagliflozin26$37,015
XifaxanRifaximin25$34,635
TradjentaLinagliptin55$30,056
JanuviaSitagliptin Phosphate40$29,661
FarxigaDapagliflozin Propanediol19$18,516
ProcritEpoetin Alfa28$14,117
Tresiba Flextouch U-100Insulin Degludec62$13,474
CreonLipase/Protease/Amylase31$10,041
MounjaroTirzepatide16$9,792
XareltoRivaroxaban12$9,605
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$9,110
EntrestoSacubitril/Valsartan12$7,642
NamzaricMemantine Hcl/Donepezil Hcl11$6,183
PradaxaDabigatran Etexilate Mesylate34$5,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$120$73,037115 claims
MerckJanuvia$20$29,66140 claims
Johnson & JohnsonProcrit, Xarelto$704$23,72240 claims
AbbVieCreon, Namzaric, Combigan$16$19,93860 claims
AstraZenecaFarxiga$87$18,51619 claims
Lilly USA, LLCMounjaro$85$9,79216 claims
NovartisEntresto$220$7,64212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coconut Creek

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →